Camp4 Therapeutics Corp
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
James B. RenacciHouse · R · OH |
CAMPCamp4 Therapeutics Corp · Stock |
Sale $15,001 - $50,000 |
Oct 20, 2015 | Oct 2, 2015 | Filing ↗ |
James B. RenacciHouse · R · OH |
CAMPCamp4 Therapeutics Corp · Stock |
Purchase $15,001 - $50,000 |
Feb 10, 2015 | Jan 28, 2015 | Filing ↗ |
Whale Activity
- Increased30
- New14
- Held10
- Decreased14
- Closed6
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| Janus Henderson Group Ltd. | 7.8M | $31.5M | — |
| Vivo Capital, LLC | 5.6M | $22.6M | increased |
| 5AM Venture Management, LLC | 5.3M | $21.3M | decreased |
| FMR LLC | 4.9M | $19.8M | increased |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.2M | $16.9M | increased |
| Trails Edge Capital Partners, LP | 3.6M | $14.6M | increased |
| Stonepine Capital Management, LLC | 2.8M | $11.3M | increased |
| BALYASNY ASSET MANAGEMENT L.P. | 2.4M | $9.7M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.1M | $8.7M | increased |
| a16z Capital Management, L.L.C. | 2.1M | $8.6M | held |
| BlackRock, Inc. | 2.0M | $8.1M | increased |
| HARBOURVEST PARTNERS LLC | 1.3M | $5.1M | held |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Gold KellyChief Financial Officer | Purchase | +10.0K | $3.96 | $40K | Aug 31, 2026 | Form 4 ↗ |
| Schwab Andrew J.Director | Sale | −400.0K | $4.04 | $1.6M | Aug 27, 2026 | Form 4 ↗ |
| Schwab Andrew J.Director | Sale | −10 | $4.50 | $45 | Aug 24, 2026 | Form 4 ↗ |
| Schwab Andrew J.Director | Sale | −32.0K | $4.50 | $144K | Aug 21, 2026 | Form 4 ↗ |
| Schwab Andrew J.Director | Sale | −114.7K | $4.54 | $521K | Aug 20, 2026 | Form 4 ↗ |
| Schwab Andrew J.Director | Sale | −45.1K | $4.76 | $215K | Aug 19, 2026 | Form 4 ↗ |
| Tardiff DanielChief Scientific Officer | Sale | −1,738 | $4.76 | $8K | Aug 19, 2026 | Form 4 ↗ |
| Young Richard ADirector | Purchase | +16.4K | $1.65 | $27K | Aug 3, 2026 | Form 4 ↗ |
| Maricich YuriChief Medical Officer | Purchase | +6,551 | $1.65 | $11K | Aug 3, 2026 | Form 4 ↗ |
| Gold KellyChief Financial Officer | Purchase | +6,551 | $1.65 | $11K | Aug 3, 2026 | Form 4 ↗ |
| Mandel-Brehm JoshChief Executive Officer · Director | Purchase | +6,551 | $1.65 | $11K | Aug 3, 2026 | Form 4 ↗ |
| Schwab Andrew J.Director · 10% owner | Grant / award | +2.9M | $1.53 | $4.5M | Sep 11, 2025 | Form 4 ↗ |
| 5AM Ventures VII, L.P.10% owner | Purchase | +2.9M | $1.53 | $4.5M | Sep 11, 2025 | Form 4 ↗ |
| Gold KellyChief Financial Officer | Purchase | +6,060 | $1.65 | $10K | Sep 11, 2025 | Form 4 ↗ |
| Mandel-Brehm JoshChief Executive Officer · Director | Purchase | +6,060 | $1.65 | $10K | Sep 11, 2025 | Form 4 ↗ |
| Maricich YuriChief Medical Officer | Purchase | +6,060 | $1.65 | $10K | Sep 11, 2025 | Form 4 ↗ |
| Young Richard ADirector | Purchase | +15.2K | $1.65 | $25K | Sep 11, 2025 | Form 4 ↗ |
| Polaris Management Co. VII, L.L.C.10% owner | Purchase | +85.5K | $1.53 | $131K | Sep 11, 2025 | Form 4 ↗ |
| Polaris Management Co. VII, L.L.C.10% owner | Purchase | +1.2M | $1.53 | $1.9M | Sep 11, 2025 | Form 4 ↗ |
| Nashat AmirDirector · 10% owner | Purchase | +85.5K | $1.53 | $131K | Sep 11, 2025 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Select Biotechnology Portfolio Fidelity Select Portfolios | 1.3M | $5.3M | 0.08% | Aug 31, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.1M | $5.0M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 453.0K | $2.0M | 0.00% | Jun 30, 2026 |
| Fidelity Growth Company Fund Fidelity Mt. Vernon Street Trust | 399.6K | $1.6M | 0.00% | Aug 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 357.2K | $1.6M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 341.8K | $1.2M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 267.7K | $1.2M | 0.01% | Jun 30, 2026 |
| Victory Science & Technology Fund Victory Portfolios III | 226.6K | $782K | 0.05% | Jul 31, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 180.3K | $714K | 0.00% | Aug 31, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 154.7K | $612K | 0.00% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list CAMP's shares (CUSIP 13463J101), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Vivo Opportunity Cayman, LLCSCHEDULE 13G/A · passive (13G) · 798.6K shares10.0%
Nov 16, 2026 · ↗ - Vivo Opportunity Cayman Fund, L.P.SCHEDULE 13G/A · passive (13G) · 798.6K shares10.0%
Nov 16, 2026 · ↗ - Vivo Opportunity, LLCSCHEDULE 13G/A · passive (13G) · 7.9M shares10.0%
Nov 16, 2026 · ↗ - Vivo Opportunity Fund Holdings, L.P.SCHEDULE 13G/A · passive (13G) · 7.9M shares10.0%
Nov 16, 2026 · ↗ - Matthew D. PerrySCHEDULE 13G/A · passive (13G) · 6.3M shares10.0%
Nov 13, 2026 · ↗ - Coastlands Capital LLCSCHEDULE 13G/A · passive (13G) · 6.3M shares10.0%
Nov 13, 2026 · ↗ - Coastlands Capital GP LLCSCHEDULE 13G/A · passive (13G) · 6.3M shares10.0%
Nov 13, 2026 · ↗ - Coastlands Capital Partners LPSCHEDULE 13G/A · passive (13G) · 6.3M shares10.0%
Nov 13, 2026 · ↗ - Coastlands Capital LPSCHEDULE 13G/A · passive (13G) · 6.3M shares10.0%
Nov 13, 2026 · ↗ - Phillip GrossSCHEDULE 13G · passive (13G) · 4.2M shares6.7%
Nov 12, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming Camp4 Therapeutics Corp as the client.
Government Contracts
No federal contract awards found for Camp4 Therapeutics Corp.
U.S. Patents
No USPTO patent applications found for Camp4 Therapeutics Corp.
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $3.5M | $652K | $350K |
| Operating income | -$52.6M | -$53.1M | -$51.9M |
| Net income | -$80.4M | -$51.8M | -$49.3M |
| Diluted EPS | -$2.65 | -$11.04 | -$124.80 |
| Operating cash flow | -$29.6M | -$45.6M | -$44.2M |
| Cash and equivalents | $109.5M | $64.0M | $38.4M |
| Total assets | $117.8M | $78.3M | $54.9M |
| Total liabilities | $70.1M | $15.2M | $16.5M |
| Shareholders' equity | $47.7M | $63.1M | -$123.7M |
As Camp4 Therapeutics Corp tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 5, 2026 ↗
Stock Splits
No stock splits in CAMP's price history.
Material Events (8-K)
- 8-K · Items 9.01Nov 5, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsSep 28, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 13, 2026
EDGAR ↗ - 8-K · Items 1.01, 3.02, 7.01, 9.01Material agreement · Unregistered sale of equity · Reg FD disclosureAug 4, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsJul 27, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 12, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureMay 14, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 7, 2026
EDGAR ↗

